INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Hanekamp Annemarie reported BNTX

Chief Commercial Officer · BioNTech SE · BioNTech SE — Performance Share Unit

Side
A
Value
—
Shares
10.1K
Price
—
Executed
May 12, 2026
Disclosed
May 13, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
May 12 executedMay 13, 2026 disclosed

BNTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BNTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$2.49M
    27.0K sh
    		Oct 8, 2026Oct 9, 2026
    traded Oct 8, 2026
    		+1dSEC FORM 4

    Evidence

    19
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.45M
    36.2K sh
    		Oct 9, 2026Oct 9, 2026
    traded Oct 9, 2026
    		+0dSEC FORM 4

    Evidence

    15
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$2.30M
    24.0K sh
    		Oct 7, 2026Oct 7, 2026
    traded Oct 7, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$2.03M
    21.0K sh
    		Oct 6, 2026Oct 6, 2026
    traded Oct 6, 2026
    		+0dSEC FORM 4

    Evidence

    15
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$7.00M
    72.0K sh
    		Oct 5, 2026Oct 6, 2026
    traded Oct 5, 2026
    		+1dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$1.64M
    17.0K sh
    		Oct 2, 2026Oct 2, 2026
    traded Oct 2, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$1.66M
    17.0K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.14M
    32.0K sh
    		Sep 30, 2026Sep 30, 2026
    traded Sep 30, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.34M
    34.0K sh
    		Sep 29, 2026Sep 30, 2026
    traded Sep 29, 2026
    		+1dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$2.66M
    27.0K sh
    		Sep 25, 2026Sep 28, 2026
    traded Sep 25, 2026
    		+3dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.35M
    34.0K sh
    		Sep 28, 2026Sep 28, 2026
    traded Sep 28, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.86M
    39.0K sh
    		Sep 24, 2026Sep 24, 2026
    traded Sep 24, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$2.98M
    30.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.23M
    33.0K sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$4.63M
    46.0K sh
    		Sep 22, 2026Sep 22, 2026
    traded Sep 22, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$2.89M
    30.0K sh
    		Sep 18, 2026Sep 18, 2026
    traded Sep 18, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.35M
    34.0K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$3.28M
    34.0K sh
    		Sep 15, 2026Sep 16, 2026
    traded Sep 15, 2026
    		+1dSEC FORM 4

    Evidence

    7
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$1.44M
    15.0K sh
    		Sep 16, 2026Sep 16, 2026
    traded Sep 16, 2026
    		+0dSEC FORM 4

    Evidence

    11
    Sahin UgurChief Executive Officer, 10% Owner
    BNTXBioNTech SE
    Open-market sale · 10b5-1 plan
    		SELL$4.08M
    41.0K sh
    		Sep 14, 2026Sep 14, 2026
    traded Sep 14, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002118987-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 12, 2026
    Published
    May 13, 2026
    Ingested by INSIDER
    Nov 5, 03:59 UTC
    Last re-read
    Nov 5, 03:59 UTC

    Extracted facts

    Filer
    Hanekamp Annemarie
    Role
    Chief Commercial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    BioNTech SE — Performance Share Unit
    Ticker
    BNTX
    Shares
    10.1K
    Price per share
    $0
    Execution date (reported)
    May 12, 2026
    Owned after transaction
    10.1K shares
    Days from execution to publication
    1

    What this establishes

    Hanekamp Annemarie filed this Form 4 reporting a grant or award of BNTX on May 12, 2026. It became public on May 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Hanekamp Annemariecik:0002118987
    Issuer
    BioNTech SEcik:0001776985

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.